Furthermore, significant variations in expression profiles and functional characteristics of key components (including VGLL4, NF2, and RASSF family members) have been documented across various malignancies (e.g., breast, hepatic, and colorectal cancers) (Zhai et al., 2023; Bevanda et al., 2025). This evidence concerns the gene VGLL4 and colorectal cancer.